In particular, the minor ginsenoside Rh2 can inhibit the growth of many kinds of cancer cells, including breast cancer, prostate cancer, hepatoma, gastric cancer, colon carcinoma, and pancreatic cancer; moreover, pre-clinical assessment of Rh2 in the PC-3 human xenograft model for prostate cancer in vivo has also been shown to be effective [11–17]. The gene discussed is RHAG; the disease is prostate cancer.